Brown Brothers Harriman Investor Services and SimCorp Forge Strategic Alliance to Provide Integrated End-to-End Technology, Data, and Services Solution for Global Asset Managers
28.1.2026 15:00:00 CET | Business Wire | Press Release
Brown Brothers Harriman (BBH), a privately held global financial services firm, and SimCorp, a leading global financial technology company, today announced a new strategic alliance to address the needs of global asset managers requiring an integrated, end-to-end technology, data, and services solution.
Enhancing both firms’ existing offerings, this solution uses BBH Infomediary to integrate SimCorp One’s front and middle office capabilities, including a real-time IBOR managed by SimCorp’s Managed Business Services, with BBH’s fund servicing and custody suite.
BBH Infomediary, BBH’s connectivity and data integration engine, will also enable a unique open architecture model that helps connect clients to third party technologies and service providers.
“For managers seeking to streamline their technology and operations across the entire investment lifecycle, this offering delivers scalability, accelerates data strategies, and allows a sharper focus on investment results,” said Shawn McNinch, Partner at BBH. “In SimCorp, we have found a firm with award-winning technology and a service model that complements our own to provide clients with the best that both firms bring to the market.”
Key benefits include:
- Accelerated transformation and time to value
- Increased oversight and control over operations
- Flexibility to integrate with third parties and retain strategic agility
“We are excited to extend the benefits of our SimCorp One platform further into our clients’ operating model with BBH’s asset servicing and Infomediary data integration capabilities to create an end-to-end solution,” said Oliver Johnson, Chief Revenue Officer at SimCorp. “BBH’s solutions and reputation for service are a great complement to our offering, providing clients with an efficient and open architecture solution.”
The first asset manager to benefit from this combined solution is systematic manager, Quoniam Asset Management, in support of their recently announced UniActive Q ETF launch.
Silke Weiser-Walther, Quoniam’s Chief Operating Officer, said, “We are delighted that two of our valued strategic providers have come together to deliver a more efficient end-to-end workflow. With their support, we can ensure that our innovative ETF products are underpinned by robust infrastructure and real time, accurate data, empowering us to deliver enhanced outcomes for our clients.”
Learn more about the BBH & SimCorp solution: BBH / SimCorp
About Brown Brothers Harriman
Brown Brothers Harriman (BBH) is a global financial services firm known for premium service and specialist expertise. For over 200 years, we have partnered with clients to navigate complexity, innovate with purpose, and succeed in evolving financial markets. Our 6,000 employees serve clients and their investments in over 90 markets across BBH’s 18 offices. As a private partnership, we are uniquely built to put clients first and create success that lasts.
BBH Investor Services is a leading provider of asset servicing and operating model solutions to global asset managers and financial institutions. Asset servicing solutions include custody, global tax services, depositary and trustee, accounting, administration, and transfer agency. Operating model solutions solve platform, data, and connectivity challenges across open-architecture operating models. We support clients’ growth, operational efficiency and resiliency, and streamline reporting and oversight. For more information see www.bbh.com.
About SimCorp
SimCorp is a provider of industry-leading integrated investment management solutions for the global buy-side. Founded in 1971, with more than 3,500 employees across five continents, SimCorp is a truly global technology leader that empowers more than half of the world’s top 100 financial companies through its integrated platform, services, and partner ecosystem.
SimCorp is a subsidiary of Deutsche Börse Group. As of 2024, SimCorp includes Axioma, the leading provider of risk management and portfolio optimization solutions for the global buy side. For more information, see www.simcorp.com.
About Quoniam
As a leading active, systematic asset manager, Quoniam manages assets totaling around 24 billion euros, employs over 120 people and has offices in Frankfurt and London.
Quoniam is not just systematic – it is science-based. We provide professional investors worldwide with smarter alpha and a more thoughtful way of investing, bringing clarity and precision to a complex world. For more information, visit www.quoniam.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260128524490/en/
Contacts
BBH contacts
Gregory Kessler
Public Relations, BBH
+1 617-772-1265
Gregory.kessler@bbh.com
Prosek Partners
+1 857-302-3712
Pro-bbh@prosek.com
SimCorp contact
Sean B. Pasternak
Global Communications, SimCorp
+1 647-975-7326
sean.pasternak@simcorp.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press Release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press Release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press Release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press Release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press Release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom